Allogene Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 13, 2025

ALLO$0.93-12.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Collaboration revenue - related party	$—	$—	$—	$22
Operating expenses:
Research and development	40,156	50,355	90,356	102,614
General and administrative	14,281	16,087	29,272	33,354
Impairment of long-lived assets	2,382	4,989	2,382	4,989
Total operating expenses	56,819	71,431	122,010	140,957
Loss from operations	(56,819)	(71,431)	(122,010)	(140,935)
Other income (expense), net:
Interest and other income, net	6,187	4,988	11,703	10,421
Interest expense	(268)	—	(418)	—
Other income (expenses), net	(43)	85	49	(844)
Total other income (expense), net	5,876	5,073	11,334	9,577
Net loss	(50,943)	(66,358)	(110,676)	(131,358)
Other comprehensive loss:
Net unrealized gain (loss) on available-for-sale investments	(88)	147	44	175
Net comprehensive loss	$(51,031)	$(66,211)	$(110,632)	$(131,183)
Net loss per share, basic and diluted	$(0.23)	$(0.35)	$(0.51)	$(0.73)
Weighted-average number of shares used in computing net loss per share, basic and diluted	218,929,548	190,026,638	217,153,948	179,577,500

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.